BR112019016635A2 - aminotriazolopiridinas como inibidores da cinase - Google Patents

aminotriazolopiridinas como inibidores da cinase Download PDF

Info

Publication number
BR112019016635A2
BR112019016635A2 BR112019016635A BR112019016635A BR112019016635A2 BR 112019016635 A2 BR112019016635 A2 BR 112019016635A2 BR 112019016635 A BR112019016635 A BR 112019016635A BR 112019016635 A BR112019016635 A BR 112019016635A BR 112019016635 A2 BR112019016635 A2 BR 112019016635A2
Authority
BR
Brazil
Prior art keywords
aminotriazolopyridines
kinase inhibitors
diastereomers
prodrugs
stereoisomers
Prior art date
Application number
BR112019016635A
Other languages
English (en)
Inventor
Guo Junqing
C. Hart Amy
E. Macor John
E. Mertzman Michael
J. Pitts William
H. Spergel Steven
Hunter Watterson Scott
Andappan Murugaiah Subbaiah Murugaiah
Chen Jie
Diane Dzierba Carolyn
Luo Guanglin
Shi Jianliang
Sit Sing-Yuen
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112019016635A2 publication Critical patent/BR112019016635A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

compostos tendo fórmula (i) (ix), e enantiômeros, e diastereômeros, estereoisômeros, sais farmaceuticamente aceitáveis e profármacos dos mesmos, são úteis como moduladores de cinase, incluindo modulação de ripk1. todas as variáveis são como definidas aqui. (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix)
BR112019016635A 2017-02-13 2018-02-12 aminotriazolopiridinas como inibidores da cinase BR112019016635A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112019016635A2 true BR112019016635A2 (pt) 2020-04-07

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019016635A BR112019016635A2 (pt) 2017-02-13 2018-02-12 aminotriazolopiridinas como inibidores da cinase

Country Status (24)

Country Link
US (2) US10913738B2 (pt)
EP (1) EP3580220B1 (pt)
JP (1) JP7097373B2 (pt)
KR (1) KR102549952B1 (pt)
CN (1) CN110520423B (pt)
AU (1) AU2018217488B2 (pt)
BR (1) BR112019016635A2 (pt)
CA (1) CA3053484A1 (pt)
CY (1) CY1124978T1 (pt)
DK (1) DK3580220T3 (pt)
EA (1) EA039808B1 (pt)
ES (1) ES2902676T3 (pt)
HR (1) HRP20212000T1 (pt)
HU (1) HUE057801T2 (pt)
IL (1) IL268614B (pt)
LT (1) LT3580220T (pt)
MA (1) MA47460A (pt)
MX (1) MX2019009555A (pt)
PL (1) PL3580220T3 (pt)
PT (1) PT3580220T (pt)
RS (1) RS62801B1 (pt)
SG (1) SG11201907335UA (pt)
SI (1) SI3580220T1 (pt)
WO (1) WO2018148626A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3580220T1 (sl) * 2017-02-13 2022-01-31 Bristol-Myers Squibb Company Aminotriazolopiridini kot kinazni inhibitorji
SI3704118T1 (sl) * 2017-10-30 2022-04-29 Bristol-Myers Squibb Company Aminoimidazopiridazini kot kinazni inhibitorji
EP3743430B1 (en) 2018-01-26 2023-08-02 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
US20210139456A1 (en) * 2018-07-09 2021-05-13 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
KR20210060516A (ko) 2018-09-13 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
CA3127701C (en) * 2019-01-25 2023-08-15 Beijing Scitech-Mq Pharmaceuticals Limited Acylamino bridged heterocyclic compound, and composition and application thereof
CN113508109B (zh) * 2019-03-22 2023-02-10 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物，其制法与医药上的用途
EP4105216A4 (en) * 2020-02-13 2024-02-28 Genfleet Therapeutics Shanghai Inc DIHYDRONAPHTHYRIDINONE COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL USE THEREOF
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
CN117460722A (zh) 2021-08-10 2024-01-26 艾伯维公司 烟酰胺ripk1抑制剂
CN116574053A (zh) * 2022-06-21 2023-08-11 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288502A1 (en) 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
AU2008328882A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
WO2010007100A1 (en) 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
EP2393813B1 (en) 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
BR112015030774A2 (pt) 2013-06-10 2017-07-25 Bayer Pharma AG novos compostos para o tratamento de câncer
EP3182974A1 (en) * 2014-08-21 2017-06-28 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
BR112018008765B1 (pt) 2015-11-05 2022-05-24 Sumitomo Chemical Company, Limited Composto heterocíclico condensado, composição e método para o controle de um artrópode nocivo
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
JP7190906B2 (ja) 2017-01-24 2022-12-16 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
SI3580220T1 (sl) * 2017-02-13 2022-01-31 Bristol-Myers Squibb Company Aminotriazolopiridini kot kinazni inhibitorji
SI3704118T1 (sl) 2017-10-30 2022-04-29 Bristol-Myers Squibb Company Aminoimidazopiridazini kot kinazni inhibitorji
EP3743430B1 (en) 2018-01-26 2023-08-02 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
DK3580220T3 (da) 2022-01-10
JP7097373B2 (ja) 2022-07-07
US20220315580A1 (en) 2022-10-06
US20190389859A1 (en) 2019-12-26
KR20190117006A (ko) 2019-10-15
PL3580220T3 (pl) 2022-02-07
SG11201907335UA (en) 2019-09-27
MA47460A (fr) 2019-12-18
CN110520423A (zh) 2019-11-29
SI3580220T1 (sl) 2022-01-31
IL268614B (en) 2021-12-01
US10913738B2 (en) 2021-02-09
AU2018217488B2 (en) 2021-09-23
IL268614A (en) 2019-10-31
WO2018148626A1 (en) 2018-08-16
JP2020507582A (ja) 2020-03-12
KR102549952B1 (ko) 2023-06-29
HRP20212000T1 (hr) 2022-04-01
CN110520423B (zh) 2022-08-23
EP3580220A1 (en) 2019-12-18
CA3053484A1 (en) 2018-08-16
PT3580220T (pt) 2022-01-03
AU2018217488A1 (en) 2019-10-03
CY1124978T1 (el) 2023-01-05
RS62801B1 (sr) 2022-02-28
EA039808B1 (ru) 2022-03-16
EP3580220B1 (en) 2021-11-17
HUE057801T2 (hu) 2022-06-28
EA201991915A1 (ru) 2019-12-30
ES2902676T3 (es) 2022-03-29
LT3580220T (lt) 2021-12-27
MX2019009555A (es) 2019-10-02

Similar Documents

Publication Publication Date Title
BR112019016635A2 (pt) aminotriazolopiridinas como inibidores da cinase
BR112018076558A2 (pt) ácidos cicloexil carbamoiloximetil triazol como an-tagonistas de lpa
EA201100992A1 (ru) Карбазолкарбоксамидные соединения, применимые в качестве ингибиторов киназы
UY37537A (es) Derivados de pirazol como inhibidores malt1
MX2021002617A (es) Indazol carboxamidas como inhibidores de cinasas.
CY1124984T1 (el) Αμινοïμιδαζοπυριδινες ως αναστολεις κινασων
MX2018012266A (es) Amidas heterociclicas como moduladores de proteinas.
DOP2020000249A (es) N-benzisoxazolilo bencenosulfonamidas como inhibidores de kat
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
MD3319967T2 (ro) Compuşi inhibitori ai căii de semnalizare Notch
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MX2022003494A (es) Azacilos sustituidos como moduladores del miembro 8 de melastatina de potencial receptor transitorio (trmp8).
MX2021006695A (es) Moduladores de trex1.
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
UY36910A (es) Benzamidas de bis isoxazolinas como compuestos insecticidas
UY36629A (es) Indazolonas como moduladores de la señalización de tnf
EA202190718A1 (ru) Индазолкарбоксамиды в качестве ингибиторов киназ
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
UY36628A (es) Indazolonas como moduladores de la señalización de tnf
MY198004A (en) Antitumoral compounds
CL2018001067A1 (es) Compuesto piranodipiridínico.
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
MX2022003769A (es) Indazol carboxamidas como inhibidores de cinasas.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]